Showing 7,301 - 7,320 results of 24,916 for search '(( 50 ((a decrease) OR (((we decrease) OR (mean decrease)))) ) OR ( 100 a decrease ))', query time: 0.78s Refine Results
  1. 7301
  2. 7302
  3. 7303
  4. 7304
  5. 7305
  6. 7306

    Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

    Published 2022
    “…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”
  7. 7307

    Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

    Published 2022
    “…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”
  8. 7308

    Synthesis and Biological Evaluation of Peripheral 5HT<sub>2B</sub> Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)

    Published 2025
    “…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl<sub>4</sub>-induced liver fibrosis mouse model. …”
  9. 7309

    Synthesis and Biological Evaluation of Peripheral 5HT<sub>2B</sub> Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)

    Published 2025
    “…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl<sub>4</sub>-induced liver fibrosis mouse model. …”
  10. 7310

    DataSheet_1_Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.docx by Daidi Zhao (5179145)

    Published 2023
    “…</p>Results<p>Of 108 patients, 80 (74.1%) initiated low-dose RTX therapy immediately after acute attack treatment and 33 (30.6%) initiated it after the first attack. During a median treatment period of 35.5 (22.0–48.8) months, significant decreases were observed in median ARR (1.1 [0.8–2.0] versus 0 [0–0.2], p < 0.001), EDSS score (3.5 [2.5–4.0] versus 2.0 [1.0–3.0], p < 0.001) and spinal cord lesion segments (5.0 [4.0–8.0] versus 3.0 [1.0–6.0], p < 0.001). …”
  11. 7311
  12. 7312
  13. 7313

    While <i>agr2</i><sup><i>+</i></sup> EMC numbers are not altered in <i>jag1a</i> mutants, <i>jag2b</i> mutants and <i>jag2b</i>-overexpressing embryos, Jagged1a, Jagged1b and Jagge... by Yu-Fen Lu (171691)

    Published 2021
    “…Scale bars, 100 μm. <b>(B).</b> Jag1a mutant protein is predicted to contain only MNNL, DSL and six EGF domains with a premature stop codon. …”
  14. 7314
  15. 7315
  16. 7316
  17. 7317

    DataSheet_2_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.docx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
  18. 7318

    DataSheet_1_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.xlsx by Joaquin Garcia-Solorio (18296686)

    Published 2024
    “…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
  19. 7319
  20. 7320